In This Article:
Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time
NEW YORK, March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 2024, at 8.30 a.m. Eastern Time on March 31, 2025.
BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, and Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, interim Chief Financial Officer, will also participate in the call. Following the prepared remarks, there will be a Q&A session with the investment community.
Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 10:00 a.m. Eastern Time on March 28, 2025.
The investment community may participate in the conference call by dialing the following numbers:
| Investor dial in: | |
| U.S. dial in: | 888-506-0062 |
| International: | 973-528-0011 |
| Participant Access Code: | 508970 |
| Webcast URL: | |
Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available until April 14, 2025.
| Teleconference Replay Number: | |
| Toll Free: | 877-481-4010 |
| International: | 919-882-2331 |
| Replay Passcode: | 52238 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative therapies for debilitating neurodegenerative diseases, leveraging both autologous and allogeneic platforms. The Company holds exclusive worldwide licensing rights for the NurOwn® technology platform, which produces autologous MSC-NTF cells. These cells have received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for amyotrophic lateral sclerosis (ALS). BrainStorm is currently planning the launch of a confirmatory Phase 3b trial in ALS with NurOwn to further evaluate its safety and efficacy. BrainStorm's exosome technology, derived from MSC-NTF cells, represents an allogeneic therapeutic platform, providing customizable, nano-carrier-based solutions for targeted delivery of bioactive molecules. These exosomes exhibit unique immunomodulatory properties and are designed to address critical pathways in neurodegenerative and respiratory diseases. The Company has completed a Phase 3 trial assessing NurOwn in ALS and advanced clinical studies of NurOwn in progressive multiple sclerosis (MS), supported by grants from the California Institute for Regenerative Medicine (CIRM) and the National MS Society (NMSS).